Literature DB >> 16449960

Integrating theories of the etiology of Crohn's disease. On the etiology of Crohn's disease: questioning the hypotheses.

William M Chamberlin1, Saleh A Naser.   

Abstract

The most prominent theory describes the Crohn's Syndrome as a dysregulated, inappropriate immune response to otherwise innocuous bowel flora in a genetically susceptible host. The autoimmune theory assumes that a specific infectious agent does not exist. Data from mouse models, impairment of the mucosal epithelial barrier and the influence of gut flora are used to support the autoimmune theory. Critics claim that the dysregulated immune responses are not the primary disorder but secondary to an underlying infection. Two other theories are also consistent with the same data. The immunodeficiency theory hypothesizes that defects in innate immunity leading to compensatory immune processes underlie the Crohn's phenotype and suggests that therapy should stimulate immunity rather than suppress it. The mycobacterial theory proposes that Mycobacterium avium subspecies paratuberculosis is one of the causes of the Crohn's Disease syndrome. Mycobacterial molecules dysregulate immune signaling pathways as part of the organisms'evolved survival strategy. If MAP were to initiate the dysregulated immune response then the necessity to hypothesize that commensal gut flora provide the antigenic stimulus would be moot. Commensal bacteria would be relegated to a secondary role of modifying the immune response rather than occupying the central role of providing the initiating antigens. Critics claim that MAP is merely a secondary invader. The three theories differ primarily by emphasizing different aspects of the same overall process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16449960

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  24 in total

1.  Managing Crohn's Disease during Pregnancy.

Authors:  Brîndusa Ana Cimpoca; Florina Nedelea; Mirona Furtuna; Gheorghe Peltecu; Anca Maria Panaitescu
Journal:  Maedica (Bucur)       Date:  2016-09

2.  Transabdominal ultrasonographic findings in goats with paratuberculosis.

Authors:  Mohamed Tharwat; Fahd Al-Sobayil; Mahmoud Hashad; Sébastien Buczinski
Journal:  Can Vet J       Date:  2012-10       Impact factor: 1.008

3.  A 60-day probiotic protocol with Dietzia subsp. C79793-74 prevents development of Johne's disease parameters after in utero and/or neonatal MAP infection.

Authors:  Robert E Click
Journal:  Virulence       Date:  2011-07-01       Impact factor: 5.882

4.  The role of bacteria in the pathogenesis of inflammatory bowel disease.

Authors:  Melissa Friswell; Barry Campbell; Jonathan Rhodes
Journal:  Gut Liver       Date:  2010-09-24       Impact factor: 4.519

5.  High prevalence of viable Mycobacterium avium subspecies paratuberculosis in Crohn's disease.

Authors:  Juan L Mendoza; Amparo San-Pedro; Esther Culebras; Raquel Cíes; Carlos Taxonera; Raquel Lana; Elena Urcelay; Fernando de la Torre; Juan J Picazo; Manuel Díaz-Rubio
Journal:  World J Gastroenterol       Date:  2010-09-28       Impact factor: 5.742

6.  Successful treatment of asymptomatic or clinically terminal bovine Mycobacterium avium subspecies paratuberculosis infection (Johne's disease) with the bacterium Dietzia used as a probiotic alone or in combination with dexamethasone: Adaption to chronic human diarrheal diseases.

Authors:  Robert E Click
Journal:  Virulence       Date:  2011-03-01       Impact factor: 5.882

7.  Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.

Authors:  Sung Jae Shin; Michael T Collins
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

8.  Systems biology analysis of gene expression during in vivo Mycobacterium avium paratuberculosis enteric colonization reveals role for immune tolerance.

Authors:  Sangeeta Khare; Sara D Lawhon; Kenneth L Drake; Jairo E S Nunes; Josely F Figueiredo; Carlos A Rossetti; Tamara Gull; Robin E Everts; Harris A Lewin; Cristi L Galindo; Harold R Garner; Leslie Garry Adams
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

9.  Correlation between rpoB gene mutation in Mycobacterium avium subspecies paratuberculosis and clinical rifabutin and rifampicin resistance for treatment of Crohn's disease.

Authors:  Daniel R Beckler; Sammer Elwasila; George Ghobrial; John F Valentine; Saleh A Naser
Journal:  World J Gastroenterol       Date:  2008-05-07       Impact factor: 5.742

10.  Mitigation of colitis with NovaSil clay therapy.

Authors:  Katherine E Zychowski; Sarah E Elmore; Kristal A Rychlik; Hoai J Ly; Felipe Pierezan; Anitha Isaiah; Jan S Suchodolski; Aline Rodrigues Hoffmann; Amelia A Romoser; Timothy D Phillips
Journal:  Dig Dis Sci       Date:  2014-09-21       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.